[Propofol protecting rats from paraquat induced lung injury]. 2006

Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
Department of Emergency, Second Affiliated Hospital, Hebei Medical University, Shijiazhuang 050000, China.

OBJECTIVE To investigate the protective efficacy of propofol against paraquat induced lung injury. METHODS One hundred and twenty-eight male Wistar rats were randomizedly divided into three groups: the control group (n = 8), the intoxication group (n = 60) and the propofol group (n = 60). One hundred and twenty rats were once administered with 5 mg/kg paraquat (PQ) by the intragastrical injection to establish the model of PQ induced lung injury. The propofol of 10 mg/kg was administered intraperitoneally in the propofol group (60 rats) twice a day for four consecutive days one hour after the rats were intoxicated while the normal saline of the same amount as propofol in the propofol group was administered in the intoxication group (60 rats) one hour after the rats were intoxicated. The intragastrical injection of 1 mg/kg normal saline was administered once in the control group (8 rats). On the first, the third, the seventh, the 14th and the 28th day after treating, the level of malondialdehyde (MDA) in plasma, bronchoalveolar lavage fluid (BALF) and lung homogenate, and the content of hydroxyproline (HPY) in lung homogenate, the cell count of BALF were detected. Meanwhile, pathological changes of lung were examined under optical microscope. RESULTS The level of MDA in plasma on the first, the third and the seventh day and in BALF and lung homogenate on the first and the third day in the propofol group [in plasma: (4.31 +/- 0.94), (4.04 +/- 0.87) and (3.24 +/- 1.14) nmol/ml; in BALF: (3.47 +/- 1.09) and (2.79 +/- 1.11) nmol/ml; in lung homogenate: (7.54 +/- 0.63) and (8.41 +/- 1.23) nmol/ml] were significantly lower than those in the intoxication group [in plasma: (10.15 +/- 3.15), (6.97 +/- 1.6 5) and (5.44 +/- 0.66) nmol/ml; in BALF: (5.58 +/- 1.19) and (4.86 +/- 1.89) nmol/ml; in lung homogenate: (10.20 +/- 2.43) and (10.71 +/- 171) nmol/ml, P < 0.05 or P < 0.01]. The total cell count of BALF on the first, the third and the seventh day after intoxication in the propofol group was significantly less than that in the intoxication group respectively (P < 0.05). The histological changes such as alveolar edema, hemorrhage and inflammatory cell infiltration in the propofol group were less than those in the PQ group. CONCLUSIONS Propofol could reduce the level of MDA and relieve paraquat induced lung injury.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D010269 Paraquat A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds. Methyl Viologen,Gramoxone,Paragreen A,Viologen, Methyl
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D006909 Hydroxyproline A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation. Oxyproline,4-Hydroxyproline,cis-4-Hydroxyproline,4 Hydroxyproline,cis 4 Hydroxyproline
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015742 Propofol An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS. Disoprofol,2,6-Bis(1-methylethyl)phenol,2,6-Diisopropylphenol,Aquafol,Diprivan,Disoprivan,Fresofol,ICI-35,868,ICI-35868,Ivofol,Propofol Abbott,Propofol Fresenius,Propofol MCT,Propofol Rovi,Propofol-Lipuro,Recofol,2,6 Diisopropylphenol,ICI 35,868,ICI 35868,ICI35,868,ICI35868

Related Publications

Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
January 2009, Journal of biomedicine & biotechnology,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
December 2014, Experimental biology and medicine (Maywood, N.J.),
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
January 2011, World journal of emergency medicine,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
January 2015, BioMed research international,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
June 2014, International immunopharmacology,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
July 2010, Life sciences,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
October 2013, International immunopharmacology,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
January 2015, Human & experimental toxicology,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
October 2018, Immunobiology,
Han-wen Shi, and Jun-li Hu, and Ying-ping Tian, and Hong-mei Huang, and Xing-hai Li, and Jian-ling Su
January 2013, PloS one,
Copied contents to your clipboard!